Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharming Group
Biotech
Pharming pays $66M for Abliva, mitochondrial disease med
Pharming is paying $66.1 million to acquire the Swedish biotech Abliva and its phase 2-stage med for a type of mitochondrial disease.
James Waldron
Dec 16, 2024 4:39am
Jade carves out exec team with Chinook vets—Chutes & Ladders
Oct 25, 2024 8:30am
Pharming uproots angioedema gene therapy collab with Orchard
May 8, 2024 6:15am
Novartis buys priority review voucher from Pharming for $21M
Jun 1, 2023 7:12am
